Aspira_OVAWatch(R) logo 1

Redefine Ovarian Care for Adnexal Masses

OvaWatch is a non-invasive blood test intended to assess the risk of ovarian cancer in patients with an adnexal mass initially evaluated as indeterminate or benign to personalize treatment.

Refine Care from Uncertainty to Confidence

High Negative Predictive Value

With a negative predictive value over 99%, a lower OvaWatch score indicates a very low probability of malignancy for confidence and peace of mind¹.

Longitudinal Monitoring Feature

The Longitudinal Monitoring feature of OvaWatch provides the patient's individualized ovarian cancer risk assessment over time, enabling a dynamic and comprehensive view of a patient’s risk profile.

Easy-to-Read Reports

Results are presented in an easy-to-read format, facilitating clear communication between healthcare providers and patients.

 A recent study indicates that using OvaWatch could have led to a potential3:

%

overall reduction in avoidable adnexal mass surgeries

%

reduction of surgical referrals among asymptomatic patients

%

reduction of surgical referrals among premenopausal patients

 

One Simple Blood Draw.
Many Benefits.

Utilizing OvaWatch could:

Provide confidence in a non-surgical, watch-and-wait approach, not uncertainty

Help back up clinical decisions with objective, biomarker-based data

Potential to reduce surgeries on adnexal masses

iStock-1225603812

Clinical Advantages for Ease & Convenience

MULTIPLE BIOMARKERS

Our products use an advanced, evidence-based algorithm incorporating multiple biomarkers

LONGITUDINAL MONITORING

This feature enables providers to perform ongoing, point-in-time, personalized ovarian cancer risk assessments for continued confidence

SIMPLE & OBJECTIVE

One simple blood draw provides an objective risk score within 48 hours

The OvaWatch Report

The OvaWatch report includes a new longitudinal monitoring feature to provide ongoing, point-in-time, personalized ovarian cancer assessments

0427_OvaWatchLMReport_Low_FinalPrint_240502 2

OvaWatch score can be viewed here

CA-125 and HE4 are included in the panel of biomarkers and will be included on the results report

The Negative Predictive Value (or the Positive Predictive Value, if appropriate) can be viewed here

The risk scores over time as indicated on the graph

AdobeStock_499225422

Enhance Standard of Care with Data-Driven Decisions

Make informed decisions at every stage with OvaWatch's advanced, evidence-based risk scores generated from a proprietary algorithm incorporating:

Age

Menopausal status

7 biomarkers (including CA-125 and HE4)

Aspira_OVAWatch(R) logo 1

OvaWatch empowers healthcare providers to transform uncertainty into fact-based ovarian care throughout the patient's journey.

Planning for surgery?

Connect with us to learn more or to order test kits

PRECAUTION: OvaWatch is intended for use as a non-invasive test to assess the risk of ovarian cancer for women with adnexal masses, evaluated by initial clinical assessment (ICA) as indeterminate or benign. In conjunction with imaging (ultrasound and/or CT) and clinical assessment, this test will support physicians in making informed clinical decisions in the management of women with adnexal masses. The test is not intended as a screening test or a stand-alone diagnostic assay.